A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs SB 623 (Primary)
- Indications Brain injuries
- Focus Therapeutic Use
- Acronyms STEMTRA
- Sponsors SanBio
- 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 26 Oct 2016 According to a SanBio media release, first patient in Japan has been enrolled in this trial.
- 21 Sep 2016 According to a SanBio media release, the trial has been initiated in Japan.